{"id":"NCT02620020","sponsor":"Regeneron Pharmaceuticals","briefTitle":"A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain","officialTitle":"A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-01-26","primaryCompletion":"2017-02-03","completion":"2017-09-13","firstPosted":"2015-12-02","resultsPosted":"2019-08-01","lastUpdate":"2020-06-16"},"enrollment":563,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Low Back Pain"],"interventions":[{"type":"DRUG","name":"Fasinumab","otherNames":["REGN475"]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Fasinumab 6 mg SC Q4W and Placebo IV Q8W","type":"EXPERIMENTAL"},{"label":"Fasinumab 9 mg SC Q4W and Placebo IV Q8W","type":"EXPERIMENTAL"},{"label":"Fasinumab 9 mg IV Q8W and Placebo SC Q4W","type":"EXPERIMENTAL"},{"label":"Placebo SC Q4W and Placebo IV Q8W","type":"EXPERIMENTAL"}],"summary":"The main objective of the trial is to evaluate the efficacy of fasinumab compared to placebo as measured by the change from baseline in the average daily Low Back Pain Intensity (LBPI) Numerical Rating Scale (NRS).\n\nSecondary objectives of the study are to evaluate the efficacy of fasinumab compared to placebo as measured by:\n\n* Change from baseline in the Roland Morris disability questionnaire (RMDQ) total score\n* Change from baseline in the Patient Global Assessment (PGA) of Low Back Pain (LBP) score\n* Change from baseline in the average daily LBPI NRS score","primaryOutcome":{"measure":"Change From Baseline to Week 16 in the Average Daily Low Back Pain Index Numeric Rating Scale (LBPI NRS) Score","timeFrame":"Baseline to Week 16","effectByArm":[{"arm":"Placebo SC Q4W and Placebo IV Q8W","deltaMin":-1.7,"sd":0.23},{"arm":"Fasinumab 6 mg SC Q4W and Placebo IV Q8W","deltaMin":-2,"sd":0.23},{"arm":"Fasinumab 9 mg SC Q4W and Placebo IV Q8W","deltaMin":-2.5,"sd":0.22},{"arm":"Fasinumab 9 mg IV Q8W and Placebo SC Q4W","deltaMin":-2.4,"sd":0.22}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3876"},{"comp":"OG000 vs OG002","p":"0.0180"},{"comp":"OG000 vs OG003","p":"0.0288"}]},"eligibility":{"minAge":"35 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":74,"countries":["United States","Canada","Czechia","Denmark","Estonia","Hungary","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":140},"commonTop":["Arthralgia","Headache","Nasopharyngitis","Paraesthesia","Pain in extremity"]}}